PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33472889-6	2021	For all tissues combined, hierarchical clustering of subtype gene expression revealed three subtypes: "luminal," "basal," and a "luminal p53-/ extracellular matrix (ECM)-like" phenotype of ECM-related genes enriched in tumor-associated urothelium, non-invasive urothelial lesions, and CIS, but rarely invasive carcinomas.	Phenobarbital	129-136	tumor protein p53	Homo sapiens	137-140	
34183353-6	2021	Luminal A/B to HER2-Enriched switching was associated with TP53 and/or PIK3CA mutations.	Phenobarbital	0-7	tumor protein p53	Homo sapiens	59-63	
34109737-6	2022	In luminal A MCF-7 cells, the selection of a drug-resistant subline from parental cells with deregulation of p53 pathways occurred.	Phenobarbital	3-10	tumor protein p53	Homo sapiens	109-112	
35489754-0	2022	The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.	Phenobarbital	95-102	tumor protein p53	Homo sapiens	56-60	
35489754-0	2022	The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.	Phenobarbital	95-102	tumor protein p53	Homo sapiens	90-94	
34043149-7	2021	Upregulation of DUXAP8 and FOXD2-AS1 was significantly associated with progesterone receptor-positive (PR+) and p53 protein expression in luminal BC patients, respectively.	Phenobarbital	138-145	tumor protein p53	Homo sapiens	112-115	
33727227-8	2021	The expression of TP53 and BRCA1 was decreased in luminal progenitor cells from normal breast tissue in BRCA1 mutation carriers, which might trigger the basal/mesenchymal transition of luminal progenitors and might result in basal-like tumor development.	Phenobarbital	50-57	tumor protein p53	Homo sapiens	18-22	
33727227-8	2021	The expression of TP53 and BRCA1 was decreased in luminal progenitor cells from normal breast tissue in BRCA1 mutation carriers, which might trigger the basal/mesenchymal transition of luminal progenitors and might result in basal-like tumor development.	Phenobarbital	185-192	tumor protein p53	Homo sapiens	18-22	
34188682-13	2021	bcl-2 (protein) and p53 significantly correlated with Luminal B and TNBC (p < 0.01).	Phenobarbital	54-61	tumor protein p53	Homo sapiens	20-23	
35217253-8	2022	Biotin-C3 peptide characterized luminal BC according to p53 status and to HER2 expression, being the biosensor a better strategy when compared to ELISA test.	Phenobarbital	32-39	tumor protein p53	Homo sapiens	56-59	
35626649-6	2022	Here, we employed the prime editing tool to revert a TP53 missense C > T mutation (L194F) in a T47D luminal A breast cancer cell line.	Phenobarbital	100-107	tumor protein p53	Homo sapiens	53-57	
35173185-7	2022	In the ER+/PR+/HER2-negative subset (n = 356) of The Cancer Genome Atlas, the non-luminal A intrinsic subtype was more prevalent in the group with mutant TP53.	Phenobarbital	82-89	tumor protein p53	Homo sapiens	154-158	
33472889-8	2021	A PanCancer Progression Panel of 681 genes unveiled pathways specific for the luminal p53-/ECM-like cluster, e.g., ECM remodeling, angiogenesis, epithelial to mesenchymal transition (EMT), cellular discohesion, cell motility involved in tumor progression; and cell proliferation and oncogenic ERBB2/ERBB3 signaling for invasive carcinomas.	Phenobarbital	78-85	tumor protein p53	Homo sapiens	86-89	
31776133-8	2020	Staining of p53 and PARP1 in breast cancer TMAs and comparison with the TCGA database indicated a higher double-positive signal in basal-like breast cancer than in luminal A or luminal B subtypes.	Phenobarbital	164-171	tumor protein p53	Homo sapiens	12-15	
31983107-4	2019	RESULTS: P53 expression was the lowest in Luminal A subtype and similar in human epidermal growth factor receptor 2 (HER-2)-overexpression subtype and triple-negative subtype, with higher expression rates than those in other molecular subtypes.	Phenobarbital	42-49	tumor protein p53	Homo sapiens	9-12